Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
This article gives an overview of candidal infections, with detailed information on oral, oesophageal, skin and invasive candidal infections.
See separate Systemic Mycoses, Fungal Lung Infections, Fungal Nail Infections and Vaginal and Vulval Candidiasis articles. Illustrations of skin and mouth candidal infections are available on DermNet NZ.
Candida spp. are yeast-like fungi which can form true hyphae and pseudohyphae. They may be part of the normal body flora, or may become an invasive pathogen. Candidal infection varies from a benign local mucosal membrane infection to disseminated disease; it can involve any organ. Severe disease is associated with an immunodeficiency - eg, malignancy, HIV infection or immunosuppressive therapy.
- Up to 60% of healthy people are asymptomatic carriers of Candida spp. (as a commensal in the gastrointestinal tract).
- Symptomatic oral infection is unusual in healthy adults but occurs in 5% of newborns and in up to 84-100% of those with HIV.
- Candidal infection is the most common cause of invasive fungal infections in hospital patients in the developed world, and mortality can be as high as 40%.
- An estimate of systemic candidal infection prevalence can be obtained from azole consumption. One European study covered 15 countries from 2005-2009 and showed a trend of increasing azole use in all countries except France.
- Non-albicans strains of Candida spp. are reported to be increasing worldwide.
Risk factors for candidal infection are:
- Broad-spectrum antibiotics.
- Central venous catheters or parenteral nutrition.
- Immunocompromise - eg, HIV, chemotherapy, corticosteroid treatment.
- Cushing's disease.
- Diabetes mellitus.
- Renal replacement therapy.
- Implanted prostheses.
- Intensive care or prolonged ventilation.
- Gastrointestinal (GI) tract surgery.
Other risk factors for mucocutaneous candidiasis are:
- Pregnancy or high-oestrogen contraceptive pill.
- Iron deficiency.
- Underlying skin disease - eg, psoriasis, dermatitis.
- General debility - eg, cancer or malnutrition.
- Local factors - heat, moisture, skin maceration, topical corticosteroids, poor dental hygiene or oral irritation.
- Extremes of age.
There are over 15 candida species which can cause disease in humans. Over 90% of mucocutaneous and invasive candidal disease is caused by one of the following five species: Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei. There has been a shift from C. albicans towards other candidal species recently, although C. albicans remains the most prevalent.
Types of oral candidiasis
- Pseudomembranous oral candidiasis (oral thrush):
- Curd-like white patches in the mouth. The white pseudomembrane can be easily removed, leaving an underlying red base that is usually painless (in contrast with leukoplakia, which cannot be rubbed off).
- Most common in neonates.
- Acute erythematous oral candidiasis (acute atrophic oral candidiasis):
- Marked erythema and soreness, especially on the tongue.
- It often follows oral thrush.
- It is common after oral antibiotics.
- Presents with marked soreness, particularly of the tongue.
- Chronic erythematous oral candidiasis (denture stomatitis or chronic atrophic oral candidiasis):
- Redness of the denture-bearing area - rarely, also soreness.
- It is common in denture users.
- Chronic plaque-like oral candidiasis (chronic hyperplastic oral candidiasis):
- Persistent firm, white plaques on the cheek or tongue, that are not easily removed.
- It is most common in smokers and men aged >30 years.
- Median rhomboid glossitis:
- A central, red, area of papillary atrophy of the tongue.
- It usually occurs in smokers or those using corticosteroid inhalers.
- It can cause recurrent/chronic candidiasis.
- Angular cheilitis:
- Redness, fissuring and soreness at the angle of the mouth.
- It can be due either to Candida spp. or to bacterial infection (mainly Staphylococcus aureus).
- Contributing factors are older age, ill-fitting dentures, immunocompromise, vitamin B12 deficiency or iron-deficiency anaemia.
Diagnosis of oral candidiasis
- Swabs/culture and serology are generally not useful because candidal organisms are commonly found in healthy people.
- Swabs may be relevant for suspected drug resistance - eg, in HIV-positive patients.
Management of oral candidiasis
Treatment - children
- Use topical treatment for ≥7 days or until 2 days after symptoms clear.
- First choice is miconazole gel but beware drug interactions and liver dysfunction.
- Otherwise, use nystatin suspension (no significant contra-indications).
- Infants - note that miconazole gel is not licensed for age <4 months; however:
- Some doctors feel this is an unnecessary limitation (it arose from concerns about choking if the gel is administered incorrectly to young babies). Although noting it is not licensed for use <4 months, the British National Formulary (BNF) states the dose for neonates and from 1 month to 1 year.
- The correct method of use is to smear 1 ml (for neonates, 1.25 ml for babies aged 1 month to 1 year) of miconazole oral gel round the mouth and gums with a finger after feeds four times a day.
- After 7 days, change to nystatin suspension if not responding to miconazole gel.
- Specialist treatment for refractory infections includes fluconazole given by mouth or itraconazole for fluconazole-resistant cases.
Treatment - immunocompetent adults
Mild or localised oral candidiasis:
- Use topical treatment for 7 days and continue until 2 days after symptoms clear.
- Options are oral miconazole gel (first-line) or nystatin suspension. NB: miconazole cautions re drug interactions and liver disease.
Extensive or severe oral candidiasis:
- Exclude risk factors - for example:
- Inhaled steroids.
- Immune compromise (HIV, etc).
- Oral fluconazole 50 mg/day for 7 days.
Candidiasis persisting after 7 days of treatment:
- If not responding to miconazole, change to nystatin.
- If taking fluconazole, continue treatment for another week.
Treatment - adults taking immunosuppressive treatment
Obtain specialist advice if the patient is taking ciclosporin, tacrolimus, or chemotherapy.
For people taking oral corticosteroids or disease-modifying antirheumatic drugs:
- Mild/localised oral candidiasis - topical treatment.
- Extensive/severe oral candidiasis - fluconazole 50-100 mg/day for 7 days.
- Follow-up after 7 days.
- Have a low threshold for admission/specialist advice; also consider if FBC is indicated.
- Have a low threshold for hospital admission.
- Obtain specialist advice before treatment if:
- There is severe/extensive oral candidiasis.
- Previous fluconazole treatment was ineffective.
- The patient is already taking antifungal prophylaxis.
- Otherwise, use oral fluconazole 100 mg/day for 7-14 days, reviewing after 7 days.
- Antiretroviral therapy is also part of the treatment and antifungal prophylaxis may help to prevent recurrence.
- Admit to hospital if there are systemic symptoms, the patient is unwell or if there are oesophageal symptoms (dysphagia or retrosternal pain) - particularly if there is immunocompromise.
- Obtain specialist advice if there is:
- Widespread candidiasis.
- No response to treatment (above).
- Recurrent episodes (may be immunocompromised).
- Breakthrough candidiasis on preventive treatment (may be drug-resistant).
- Chronic plaque-like oral candidiasis not responding to treatment (needs biopsy).
Symptomatic oral candidal infection is rare in healthy adults - if present, consider investigating for underlying illness - eg, immunocompromise.
Prevention of oral candidiasis
- Patients taking oral/inhaled steroids - good inhaler technique, spacer device, rinse mouth with water after use.
- Denture wearers - thorough cleaning of dentures, leave them out at night, ensure they fit correctly.
- Smoking cessation.
- Dysphagia, pain on swallowing food or fluids and/or retrosternal pain, usually with oropharyngeal candidiasis.
- This combination of symptoms is predictive of oesophageal candidiasis.
- It is most often associated with treatment of haematopoietic or lymphatic malignancies.
- In HIV-positive patients, it is an AIDS-defining illness.
- A therapeutic trial of fluconazole for patients is useful; most patients will respond within 7 days of treatment.
- Definitive diagnosis is by endoscopy.
Management of oesophageal candidiasis
- Treatment is usually advised by secondary care. Consider admission to hospital - oesophageal candidiasis can be a life-threatening infection.
- Treat for 14-21 days; the following treatment options are suggested:
- First-line treatment options:
- Oral fluconazole (200-400 mg daily).
- If oral treatment cannot be tolerated, intravenous (IV) fluconazole or an echinocandin - eg, caspofungin, or micafungin.
- Second-line treatments are oral itraconazole oral solution, oral posaconazole or IV or oral voriconazole.
- First-line treatment options:
- For AIDS patients, antiretroviral therapy is advised to prevent recurrence.
See separate Vaginal and Vulval Candidiasis article.
Candidal skin infections
- Soreness and itching.
- The appearance of the affected skin is variable; there may be:
- Red, moist skin area with a ragged, peeling edge and possibly pustules or papules at the margin. There may be satellite lesions (pustules or erythema) surrounding the margin.
- Pustules which are thin-walled with a red base.
- Yellow-white scale on the surface (looks like curds).
- In the foot or hand web spaces - maceration (moist damaged skin) with a thick horny layer.
There are different forms of cutaneous candidiasis:
- Intertrigo (skin fold infection).
- Candidal nail infections - chronic paronychia or onychomycosis. See separate Fungal Nail Infections article.
- Napkin dermatitis.
- Chronic mucocutaneous candidiasis:
- A rare condition, usually beginning in childhood, with persistent and prolonged candidal infections of the skin and mucous membranes.
- May be due to genetic predisposition, endocrinopathies, T-cell disorders or low immunoglobulin levels.
- Candidal folliculitis.
- Generalised cutaneous candidiasis (rare): a widespread rash, worse in skin folds and extremities, with pruritus.
- Skin lesions in patients with invasive candidiasis - see 'Invasive candidal infections', below.
When to investigate
Swabs are not usually required but take standard bacteriology swabs for microscopy and culture if:
- The diagnosis is unclear, or bacterial infection is suspected.
- There is no improvement after initial treatment.
- The patient is immunocompromised.
- Systemic treatment is considered.
Look for an underlying cause if there is widespread or recurrent candidiasis (see 'Risk factors', above).
- General measures: avoid occlusion of skin, avoid obesity, keep skin dry, wash with emollients as soap substitutes and dry thoroughly after washing.
- First-line pharmacological treatment is usually a topical imidazole cream - eg, clotrimazole, econazole, ketoconazole, or miconazole. (Ketoconazole is licensed for adults only.)
- Topical terbinafine is an alternative.
- If there is problematic itch or inflammation, consider adding a mild corticosteroid cream for 7-14 days.
- Oral fluconazole 50 mg/day for 2-4 weeks if:
- Topical treatment is ineffective.
- There is widespread infection.
- The patient is immunocompromised (depending on the severity of infection and the level of immunocompromise).
- Review after 2 weeks of fluconazole treatment.
- If not improving, obtain specialist advice.
- Chronic mucocutaneous candidiasis is a difficult condition to treat. Systemic antifungals are the mainstay of treatment; fluconazole and itraconazole are first-line options. Oral ketoconazole was withdrawn in 2013 because of concerns about liver damage.
The term invasive candidiasis encompasses a variety of severe candidal infections:
- Candidaemia - the most common form.
- Deep-seated tissue candidiasis. Any internal organ can be affected (see 'Disseminated candidiasis (deep organ infection)', below).
Usually there is an underlying risk factor - eg, immunocompromise, critical illness, abdominal surgery, haemodialysis, implants or indwelling catheters.
Invasive candidiasis is life-threatening and has a mortality of up to 40%.
- Prompt diagnosis is important but often difficult.
- Have a low index of suspicion and prompt treatment in at-risk patients - eg, in neutropenic patients, start antifungal therapy if there are >4 days of persistent fever despite antibiotics.
- Blood cultures should be taken but lack sensitivity (21-71%) and usually become positive late.
- Culture of body fluids or tissues as appropriate.
- Various rapid tests are available to identify Candida spp. from cultures.
- Antifungal susceptibility tests are important in view of the increasing problem of resistance.
- Serological tests:
- These detect components of the fungal cell wall or antibodies directed against these antigens (eg, mannan or anti-mannan). Several tests are now commercially available although their sensitivity and specificity are variable.
- Molecular-based polymerase chain reaction (PCR) tests for detection of candidal DNA.
- Ultrasound and/or CT scans are useful in abdominal or renal tract infections. Again, radiological signs may appear late.
- Echocardiography for suspected cardiac involvement.
- Tissue biopsy and culture - if feasible.
- Endoscopy for suspected upper GI infections.
- Risk factors, including prolonged IV catheterisation.
- Fever/chills unresponsive to broad-spectrum antibiotics.
- May have macronodular skin lesions, candidal endophthalmitis, multi-organ infection or, rarely, septic shock.
- Characteristic skin lesions may be present in some patients with candidaemia or disseminated candidiasis. These are erythematous, firm, non-tender macronodular lesions with discrete borders. Biopsy of these lesions shows yeast cells, hyphae, or pseudohyphae, with cultures positive for Candida spp. in approximately 50% of cases.
Current treatment guidelines recommend:
- First-line treatment:
- Non-neutropenic patients - IV fluconazole or an echinocandin (echinocandins are preferred for severe illness, recent azole exposure or likely C. glabrata).
- Neutropenic patients - an echinocandin, or a lipid formulation of amphotericin (more potential for toxicity). Fluconazole can be used in less ill patients with no recent azole exposure.
- Other management strategies and second-line treatments:
- Voriconazole (may be an alternative or a step-down treatment).
- Transition to fluconazole in those initially treated with an echinocandin or amphotericin may take place when the person is stable and if the isolate has confirmed susceptibility.
- Remove central venous catheters as soon as possible in non-neutropenic patients if thought to be a likely cause.
- Fundoscopy (dilated) within the first week for non-neutropenic patients (ocular lesions (mostly chorioretinitis) occur in 16% of candidaemias and can have late presentation). For neutropenic patients, fundoscopy should take place within a week of recovery from neutropenia.
- Test for treatment susceptibility.
- Blood cultures to assess for clearance of candidal infection daily or alternate days.
- If there are no complications, continue treatment for 2 weeks after the patient is clinically well, there is resolution of neutropenia and clearance from the bloodstream.
Disseminated candidiasis (deep organ infection)
- Any internal organ, or multiple organs, may be affected (listed below).
- It results from blood-borne spread or direct inoculation of a sterile site such as the peritoneal cavity.
- It presents with fever unresponsive to broad-spectrum antibiotics and features of sepsis; there may be septic shock.
- Blood cultures may be negative in about 50% of cases.
Treatment of disseminated candidiasis
- Systemic antifungal therapy (prolonged treatment in many cases): specific recommendations for different organ infections are detailed in current USA-based guidelines.
- Removal of the source of infection or of the precipitating factors, if feasible (eg, remove indwelling devices, treatment of immunocompromise).
- Surgical debridement may be appropriate.
Types of disseminated candidiasis
The following deep organ candidal infections can occur.
- Suppurative thrombophlebitis.
- Candidal infection of pacemakers, implantable cardiac defibrillators and ventricular assist devices.
- Candida spp. isolated from respiratory secretions - this rarely indicates invasive candidiasis; candidal infection is common in respiratory secretions and cultures from them.
- Candidal pneumonia, lung abscess or tracheobronchitis - these are rare.
- Laryngeal candidiasis - is uncommon and mainly associated with malignancies.
- Candidal peritonitis - may be a complication of peritoneal dialysis.
- Chronic disseminated candidiasis (hepatosplenic candidiasis):
- This is a form of systemic candidiasis, occurring in patients with a haematological malignancy and neutropenia. It develops during the recovery phase of a neutropenic episode.
- Clinical features are fever (unresponsive to broad-spectrum antibiotics), abdominal pain, tender hepatosplenomegaly, vomiting, dysphagia and jaundice.
- It may be a form of inflammatory immune reconstitution syndrome.
- Non-oesophageal GI candidiasis:
- This most commonly involves the stomach or small intestine.
- Candidal cholecystitis (rare).
- Asymptomatic cystitis:
- Candida spp. are found in up to 10% of urine cultures; treatment is not usually indicated, except in high-risk patients - eg, low birth-weight neonates, neutropenia, or urological procedures.
- Symptomatic cystitis.
- Urinary fungus balls:
- These are due to accumulation of fungal material in the renal pelvis; the balls can occur anywhere in the urinary collecting system.
- May cause intermittent urinary tract obstruction with anuria and renal insufficiency.
- A rare complication of fungal infection.
- Candidal prostatitis and epididymo-orchitis (rare).
- Granulomatous vasculitis.
- Diffuse cerebritis with microabscesses.
- Mycotic aneurysms.
Candidal osteo-articular infection:
- Septic arthritis.
- Osteomyelitis (including sternal osteomyelitis following sternotomy).
- Infection of prosthetic device.
- Costochondritis (rare).
- Myositis (rare).
Obstetric and neonatal candidal infections
- This is an important cause of mortality and morbidity in very low birth-weight (VLBW) infants; those who are extremely preterm or low birth-weight are most at risk.
- C. albicans and C. parapsilosis are the most common species found in neonates.
- A Cochrane review found there were insufficient data to inform practice with regard to treatment. The usual therapeutic agents are amphotericin and fluconazole. Other azoles such as voriconazole and the echinocandins are being studied and may have a role to play.
- There is some evidence to support the use of prophylactic oral, topical or systemic antifungal agents in VLBW infants in the neonatal intensive care unit.
- May cause fetal death.
- May result in cutaneous congenital candidiasis - a very rare disease comprising a generalised rash at, or shortly after, birth and usually without other signs or symptoms, which is always secondary to candidal chorioamnionitis; it is essentially benign and self-limiting.
Placental infection is rare. In vitro fertilisation is a risk factor.
Did you find this information useful?
Further reading & references
- Ng TB, Cheung RC, Ye XJ, et al; Pharmacotherapy approaches to antifungal prophylaxis. Expert Opin Pharmacother. 2012 Jun 20.
- Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al; Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis. 2012 Jan 18(1):86-90. doi: 10.3201/eid1801.110556.
- Blyth CC, Hale K, Palasanthiran P, et al; Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev. 2010 Feb 17 (2):CD006343.
- Cortegiani A, Russotto V, Maggiore A, et al; Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. 2016 Jan 16 (1):CD004920. doi: 10.1002/14651858.CD004920.pub3.
- Candidal infection; DermNet NZ
- Pappas PG, Kauffman CA, Andes DR, et al; Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15 62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.
- Candida - oral; NICE CKS, July 2013 (UK access only)
- Kullberg BJ, Arendrup MC; Invasive Candidiasis. N Engl J Med. 2015 Oct 8 373(15):1445-56. doi: 10.1056/NEJMra1315399.
- Pagano L, Lumb J; Update on invasive fungal disease. Future Microbiol. 2011 Sep 6(9):985-9.
- Sardi JC, Scorzoni L, Bernardi T, et al; Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013 Jan 62(Pt 1):10-24. doi: 10.1099/jmm.0.045054-0. Epub 2012 Nov 22.
- British National Formulary for Children; NICE Evidence Services (UK access only)
- Pienaar ED, Young T, Holmes H; Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev. 2010 Nov 10 (11):CD003940. doi: 10.1002/14651858.CD003940.pub3.
- Treatment of opportunistic infection in HIV-seropositive individuals; British HIV Association (2011)
- Candida - skin; NICE CKS, January 2014 (UK access only)
- Eyerich K, Eyerich S, Hiller J, et al; Chronic mucocutaneous candidiasis, from bench to bedside. Eur J Dermatol. 2010 May-Jun 20(3):260-5. Epub 2010 Feb 5.
- British National Formulary; NICE Evidence Services (UK access only)
- Oral ketoconazole: do not prescribe or use for fungal infections - risk of liver injury outweighs benefits; Drug Safety Update, Medicines and Healthcare products Regulatory Agency, Aug 2013
- Coyle EA; Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU. J Pharm Pract. 2010 Feb 23(1):33-7.
- Kullberg BJ, Verweij PE, Akova M, et al; European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011 Sep 17 Suppl 5:1-12. doi:
- Matuszkiewicz-Rowinska J; Update on fungal peritonitis and its treatment. Perit Dial Int. 2009 Feb 29 Suppl 2:S161-5.
- Praz V, Burruni R, Meid F, et al; Fungus ball in the urinary tract: A rare entity. Can Urol Assoc J. 2014 Jan-Feb 8(1-2):E118-20. doi: 10.5489/cuaj.1254.
- Shah CP, McKey J, Spirn MJ, et al; Ocular candidiasis: a review. Br J Ophthalmol. 2008 Apr 92(4):466-8.
- Clerihew L, McGuire W; Antifungal therapy for newborn infants with invasive fungal infection. Cochrane Database Syst Rev. 2012 Jun 13 6:CD003953. doi: 10.1002/14651858.CD003953.pub3.
- Spiliopoulou A, Dimitriou G, Jelastopulu E, et al; Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and Mycopathologia. 2012 Apr 173(4):219-28. Epub 2011 Nov 11.
- Austin N, McGuire W; Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2013 Apr 30 4:CD003850. doi: 10.1002/14651858.CD003850.pub4.
- Meizoso T, Rivera T, Fernandez-Acenero MJ, et al; Intrauterine candidiasis: report of four cases. Arch Gynecol Obstet. 2008 Aug 278(2):173-6. Epub 2008 Jan 24.
- Huang M, Cham EM, Eppes CS, et al; Placental and Fetal Findings in Intrauterine Candida lusitaniae infection following in vitro fertilization and embryo transfer. Pediatr Dev Pathol. 2012 Mar-Apr 15(2):127-31. Epub 2011 Aug 24.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.